Stock ScreenerStock IdeasZen Ratings + Top AnalystsStocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: Nov 7, 2025The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.
Stock ScreenerStock IdeasZen Ratings + Top Analysts
Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | DEXCOM INC | A | $59.28 | B | $23.02 | 157.53% | 32.22x | 28.16x | 5.13x | 8.48x | 1.79x | $1.06B | 4.58% | $2.73B | 6.97 | $23.81B | 19.47 |
| SGHC | SUPER GROUP (SGHC) LTD | A | $12.21 | C | $7.31 | 67.04% | 24.52x | 25.91x | 2.47x | 7.13x | 1.03x | N/A | N/A | $866.28M | 1.71 | $5.72B | N/A |
| GTES | GATES INDUSTRIAL CORP PLC | A | $21.85 | B | $15.11 | 44.57% | 23.75x | 14.25x | 1.65x | 1.67x | 0.83x | $324.70M | 5.75% | $3.37B | 13.05 | $7.32B | 10.88 |
| TGTX | TG THERAPEUTICS INC | A | $34.04 | B | $15.20 | 123.88% | 83.02x | 44.13x | 11.00x | 19.54x | 0.99x | -$59.24M | -1.19% | $276.43M | 1.88 | $5.52B | 56.64 |
| SEE | SEALED AIR CORP | A | $36.59 | B | $24.09 | 51.91% | 11.84x | 11.43x | 1.01x | 4.52x | 2.24x | $385.90M | 7.17% | $1.19B | 8.09 | $9.37B | 9.54 |
| MMSI | MERIT MEDICAL SYSTEMS INC | A | $87.11 | C | $34.35 | 153.61% | 43.34x | 23.02x | 3.49x | 3.38x | 1.43x | $206.93M | 4.01% | $1.53B | 25.82 | $5.59B | 17.87 |
| RSI | RUSH STREET INTERACTIVE INC | A | $16.62 | C | $4.70 | 253.80% | 50.36x | 41.17x | 1.50x | 28.65x | 2.23x | $91.18M | 5.70% | $133.08M | 1.38 | $3.54B | -106.99 |
| MIRM | MIRUM PHARMACEUTICALS INC | A | $70.09 | C | N/A | N/A | -57.93x | -100.73x | 8.12x | 13.80x | N/A | $8.63M | 0.25% | $255.16M | 5.13 | $3.61B | -209.88 |
| EXTR | EXTREME NETWORKS INC | A | $17.65 | C | $4.99 | 253.63% | 252.14x | 17.43x | 1.99x | 34.42x | 1.43x | $94.80M | 4.04% | $68.56M | 0.52 | $2.39B | 36.36 |
| SPNT | SIRIUSPOINT LTD | A | $19.42 | B | $21.01 | -7.58% | 11.70x | 8.54x | 0.80x | 1.03x | 0.64x | $236.50M | 10.43% | $2.21B | 18.93 | $2.23B | 6.59 |
| IHS | IHS HOLDING LTD | A | $6.63 | B | $5.14 | 28.98% | 19.50x | 18.22x | 1.29x | -8.21x | 0.78x | $787.93M | 35.41% | -$270.80M | -0.81 | $5.53B | N/A |
| ARDT | ARDENT HEALTH INC | A | $14.67 | A | $14.52 | 1.04% | 7.89x | 7.82x | 0.33x | 1.67x | 1.48x | $108.13M | 5.25% | $1.25B | 8.94 | $3.83B | 7.07 |
| NTCT | NETSCOUT SYSTEMS INC | A | $27.31 | A | N/A | N/A | -5.33x | 11.47x | 2.38x | 1.25x | N/A | $212.26M | 10.85% | $1.56B | 21.79 | $1.53B | -5.20 |
| FIVN | FIVE9 INC | A | $22.76 | A | $10.51 | 116.53% | 175.08x | 7.71x | 1.58x | 2.45x | 0.87x | $109.81M | 6.29% | $717.38M | 9.36 | $2.35B | 23.90 |
| BLBD | BLUE BIRD CORP | A | $51.36 | B | $38.35 | 33.93% | 14.15x | 11.77x | 1.14x | 7.34x | 1.11x | $143.11M | 8.83% | $221.85M | 7.03 | $1.55B | 8.80 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | A | $7.17 | B | N/A | N/A | -39.83x | 81.38x | 2.69x | -3.57x | N/A | $15.76M | 1.05% | -$421.59M | -2.01 | $2.16B | 33.98 |
| DCO | DUCOMMUN INC | A | $91.86 | C | $43.72 | 110.10% | 38.76x | 24.63x | 1.73x | 1.97x | 1.14x | $22.85M | 1.67% | $693.01M | 46.65 | $1.61B | 16.31 |
| CRTO | CRITEO SA | A | $22.28 | A | $39.72 | -43.91% | 7.14x | 4.67x | 0.60x | 1.04x | 0.38x | $225.50M | 19.25% | $1.13B | 21.52 | $1.03B | 4.72 |
| ANAB | ANAPTYSBIO INC | A | $36.00 | C | N/A | N/A | -13.14x | -8.47x | 5.91x | -33.89x | N/A | -$145.32M | -14.50% | -$29.42M | -1.06 | $1.23B | -15.02 |
| EVER | EVERQUOTE INC | A | $24.99 | B | $12.95 | 93.02% | 16.77x | 18.54x | 1.40x | 5.14x | 2.18x | $83.61M | 9.24% | $174.93M | 4.83 | $755.64M | 12.70 |
| NRDS | NERDWALLET INC | A | $12.04 | B | $6.47 | 85.98% | 30.87x | 24.93x | 1.22x | 2.41x | 1.07x | $55.30M | 6.19% | $371.60M | 5.01 | $804.93M | 15.72 |
| UDMY | UDEMY INC | A | $5.32 | B | N/A | N/A | -177.33x | 10.26x | 1.00x | 3.51x | N/A | $64.36M | 8.06% | $221.81M | 1.48 | $554.56M | 19.21 |
| TBPH | THERAVANCE BIOPHARMA INC | A | $14.95 | B | N/A | N/A | 59.80x | 15.87x | 9.71x | 3.35x | N/A | $244.78M | 32.63% | $224.85M | 4.48 | $516.60M | 10.67 |
| AKBA | AKEBIA THERAPEUTICS INC | A | $2.12 | C | N/A | N/A | -9.64x | -815.38x | 2.70x | 22.65x | N/A | -$34.69M | -6.93% | $24.58M | 0.10 | $492.05M | 45.26 |
| EGHT | 8X8 INC | A | $2.20 | B | N/A | N/A | -13.75x | 7.22x | 0.41x | 2.34x | N/A | $42.80M | 14.45% | $128.19M | 0.95 | $611.99M | 14.68 |
| NATR | NATURES SUNSHINE PRODUCTS INC | A | $14.13 | A | $9.86 | 43.25% | 18.35x | 14.90x | 0.56x | 1.52x | 0.98x | $22.36M | 8.60% | $163.68M | 8.89 | $183.48M | 4.23 |
| ELMD | ELECTROMED INC | A | $25.26 | B | $8.88 | 184.59% | 28.38x | 25.01x | 3.34x | 4.88x | 2.54x | $11.13M | 5.21% | $43.21M | 5.11 | $195.61M | 17.28 |
| INFU | INFUSYSTEM HOLDINGS INC | A | $10.00 | C | $3.33 | 200.61% | 38.46x | 37.71x | 1.45x | 3.67x | 2.05x | $18.76M | 9.19% | $55.47M | 2.72 | $227.10M | 9.40 |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have access to Premium? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.